Amneal's Adcomfo wins European Commission approval
AMRX•The European Commission granted marketing authorization for Amneal Pharmaceuticals' Adcomfo, a biosimilar to Xolair. The U.S. application remains under FDA review.
1. European authorization
The European Commission granted marketing authorization for Amneal Pharmaceuticals' Adcomfo (omalizumab), a biosimilar to Xolair. The U.S. application for the proposed biosimilar remains under FDA review.




